CR9830A - Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa - Google Patents

Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa

Info

Publication number
CR9830A
CR9830A CR9830A CR9830A CR9830A CR 9830 A CR9830 A CR 9830A CR 9830 A CR9830 A CR 9830A CR 9830 A CR9830 A CR 9830A CR 9830 A CR9830 A CR 9830A
Authority
CR
Costa Rica
Prior art keywords
secretase
phenyl
amino
difluorometoxi
inhibition
Prior art date
Application number
CR9830A
Other languages
English (en)
Inventor
Michael Sotirios Malamas
James Joseph Erdei
William Floyd Fobare
Dominick Anthony Quagliato
Schuyler Adam Antane
Albert Jean Robichaud
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9830A publication Critical patent/CR9830A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88Nitrogen atoms, e.g. allantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41681,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion suministra un compuesto de 2-amino-5-[4-(difluorometoxi)fenil]-5-3,5-dihidro-fenilimidazol-4-ona de formula I. La presente invencion tambien suministra metodos para el uso del mismo para inhibir la B-secretasa (BACE) y tratar los depositos B-amiloides y las maranas neurofibrilares.
CR9830A 2005-09-26 2008-03-26 Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa CR9830A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72058905P 2005-09-26 2005-09-26

Publications (1)

Publication Number Publication Date
CR9830A true CR9830A (es) 2008-05-21

Family

ID=37693581

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9830A CR9830A (es) 2005-09-26 2008-03-26 Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa

Country Status (19)

Country Link
US (2) US7423158B2 (es)
EP (2) EP1928841A1 (es)
JP (1) JP2009509957A (es)
KR (1) KR20080050430A (es)
CN (1) CN101273018A (es)
AR (1) AR056536A1 (es)
AU (1) AU2006294620A1 (es)
BR (1) BRPI0616757A2 (es)
CA (1) CA2623245A1 (es)
CR (1) CR9830A (es)
EC (1) ECSP088286A (es)
GT (1) GT200600432A (es)
IL (1) IL189650A0 (es)
NO (1) NO20080942L (es)
PE (1) PE20070461A1 (es)
RU (1) RU2008106936A (es)
TW (1) TW200808735A (es)
WO (1) WO2007038271A1 (es)
ZA (1) ZA200802636B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
MXPA06014792A (es) * 2004-06-16 2007-02-16 Wyeth Corp Difenilimidazopirimidina y aminas imidazol como inhibidores de ??-secretasa.
JP2008503459A (ja) * 2004-06-16 2008-02-07 ワイス β−セクレターゼを阻害するためのアミノ−5,5−ジフェニルイミダゾロン誘導体
AR050184A1 (es) 2004-07-28 2006-10-04 Schering Corp Inhibidores macrociclicos de beta-secretasa
BRPI0606690A2 (pt) 2005-01-14 2009-07-14 Wyeth Corp composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica
RU2007124935A (ru) * 2005-02-01 2009-03-10 Вайет (Us) АМИНОПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКТРЕТАЗЫ
JP2008530103A (ja) 2005-02-14 2008-08-07 ワイス β−セクレターゼ阻害剤としてのアゾリルアシルグアニジン
SG162790A1 (en) 2005-06-14 2010-07-29 Schering Corp Aspartyl protease inhibitors
WO2006138265A2 (en) * 2005-06-14 2006-12-28 Schering Corporation Heterocyclic aspartyl protease inhibitors, preparation and use thereof
BRPI0613578A2 (pt) * 2005-06-30 2012-01-17 Wyeth Corp composito da fórmula i; uso de um composto de fórmula i; e composição farmacêutica
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
US20100143896A1 (en) * 2005-09-05 2010-06-10 Jun Fujita Sequence capable of enhancing the expression of gene under moderately low temperature
WO2007049532A1 (ja) 2005-10-25 2007-05-03 Shionogi & Co., Ltd. アミノジヒドロチアジン誘導体
AU2006333049A1 (en) * 2005-12-19 2007-07-12 Wyeth 2-amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
BRPI0712780A2 (pt) 2006-06-12 2012-09-11 Schering Corp inibidores de aspartil protease heterocìclicos
US7700606B2 (en) * 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
EP2064201A2 (en) * 2006-09-21 2009-06-03 Wyeth Indolylalkylpyridin-2-amines for the inhibition of beta-secretase
AU2007332750A1 (en) * 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors containing a tricyclic ring system
JP2010512389A (ja) 2006-12-12 2010-04-22 シェーリング コーポレイション アスパルチルプロテアーゼ阻害剤
WO2008076043A1 (en) * 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5,5-diaryl-imidazol-4-ones
CL2008000784A1 (es) * 2007-03-20 2008-05-30 Wyeth Corp Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co
CL2008000791A1 (es) * 2007-03-23 2008-05-30 Wyeth Corp Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm
WO2008133274A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. 環式基で置換されたアミノジヒドロチアジン誘導体
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
JP2011518224A (ja) * 2008-04-22 2011-06-23 シェーリング コーポレイション Bace−1阻害剤としてのチオフェニル置換2−イミノ−3−メチルピロロピリミジノン化合物、組成物、およびそれらの使用
WO2009151098A1 (ja) 2008-06-13 2009-12-17 塩野義製薬株式会社 βセクレターゼ阻害作用を有する含硫黄複素環誘導体
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2010030954A1 (en) 2008-09-11 2010-03-18 Amgen Inc. Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Bace1阻害活性を有する2−アミノピリミジン−4−オンおよび2−アミノピリジン誘導体
EA020875B1 (ru) 2009-03-13 2015-02-27 Вайтаи Фармасьютиклз, Инк. Ингибиторы бета-секретазы
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
CN102812005B (zh) 2010-02-24 2014-12-10 生命医药公司 β-分泌酶抑制剂
JP2013522305A (ja) 2010-03-15 2013-06-13 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのスピロ−四環式環化合物
JP5584352B2 (ja) 2010-03-15 2014-09-03 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
WO2012019056A1 (en) 2010-08-05 2012-02-09 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
CA2816285A1 (en) 2010-10-29 2012-05-03 Shionogi & Co., Ltd. Naphthyridine derivative
WO2012071279A1 (en) 2010-11-23 2012-05-31 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
EP2673279A1 (en) 2011-02-07 2013-12-18 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
US8962859B2 (en) 2011-02-15 2015-02-24 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
EP2758406A1 (en) 2011-09-21 2014-07-30 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β-分泌酶抑制劑
EP3607946B1 (en) 2012-03-19 2023-02-22 Buck Institute for Research on Aging App specific bace inhibitors (asbis) and uses thereof
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β-分泌酶抑制劑
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
US9416129B2 (en) 2012-10-17 2016-08-16 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use
WO2014062549A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US10202355B2 (en) 2013-02-12 2019-02-12 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
CN103408573B (zh) * 2013-07-12 2015-12-23 上海工程技术大学 硼酸衍生物及其制备方法和应用
KR20180090778A (ko) * 2015-08-27 2018-08-13 난트뉴로, 엘엘씨 App-선택적 bace 억제를 위한 조성물 및 그의 용도
CN106749033A (zh) * 2015-11-25 2017-05-31 中国人民解放军军事医学科学院毒物药物研究所 乙内酰脲类化合物及其作为β-分泌酶抑制剂的用途
CN113087667B (zh) * 2021-03-24 2022-06-24 五邑大学 一种咪唑啉酮衍生物的合成方法
WO2024201390A1 (en) * 2023-03-29 2024-10-03 Simon Fraser University Methods and reagents for synthesizing haloaldehydes, and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE45198B1 (en) 1976-06-05 1982-07-14 Wyeth John & Brother Ltd Guanidine derivatives
DE2901362A1 (de) 1978-01-25 1979-07-26 Sandoz Ag Guanidinderivate, ihre herstellung und verwendung
GB1588096A (en) 1978-05-20 1981-04-15 Wyeth & Bros Ltd John Pyrrole derivatives
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
ZA967800B (en) 1995-09-20 1997-04-03 Yamanouchi Pharma Co Ltd Heteroaryllsubstituted acryloylguanidine derivatives and pharmaceutical compositions comprising them
GB9611046D0 (en) 1996-05-25 1996-07-31 Wivenhoe Techn Ltd Pharmacological compounds
GB2323841A (en) 1997-04-04 1998-10-07 Ferring Bv Group Holdings Pyridine derivatives with anti-tumor and anti-inflammatory activity
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6492408B1 (en) 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
DE10024319A1 (de) 2000-05-17 2001-11-22 Merck Patent Gmbh Bisacylguanidine
DE10046993A1 (de) 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
WO2003053938A1 (en) 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
WO2003064396A1 (en) 2002-02-01 2003-08-07 Elan Pharmaceuticals, Inc. Hydroxyalkanoyl aminopyrazoles and related compounds
US6974829B2 (en) 2002-05-07 2005-12-13 Elan Pharmaceuticals, Inc. Succinoyl aminopyrazoles and related compounds
WO2004058727A1 (en) * 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
EP1644354A1 (en) 2003-07-01 2006-04-12 Bayer CropScience GmbH 3-pyridylcarboxamide derivatives as pesticidal agents
MY149978A (en) * 2003-12-15 2013-11-15 Merck Sharp & Dohme Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2008503459A (ja) * 2004-06-16 2008-02-07 ワイス β−セクレターゼを阻害するためのアミノ−5,5−ジフェニルイミダゾロン誘導体
MXPA06014792A (es) 2004-06-16 2007-02-16 Wyeth Corp Difenilimidazopirimidina y aminas imidazol como inhibidores de ??-secretasa.
BRPI0606690A2 (pt) 2005-01-14 2009-07-14 Wyeth Corp composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica
RU2007124935A (ru) 2005-02-01 2009-03-10 Вайет (Us) АМИНОПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКТРЕТАЗЫ
WO2006088705A1 (en) 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
JP2008530103A (ja) 2005-02-14 2008-08-07 ワイス β−セクレターゼ阻害剤としてのアゾリルアシルグアニジン
WO2006088694A1 (en) 2005-02-14 2006-08-24 Wyeth SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
BRPI0613578A2 (pt) 2005-06-30 2012-01-17 Wyeth Corp composito da fórmula i; uso de um composto de fórmula i; e composição farmacêutica
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
AU2006333049A1 (en) 2005-12-19 2007-07-12 Wyeth 2-amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
US7700606B2 (en) 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase

Also Published As

Publication number Publication date
US20090012139A1 (en) 2009-01-08
WO2007038271A9 (en) 2008-05-08
JP2009509957A (ja) 2009-03-12
CA2623245A1 (en) 2007-04-05
AR056536A1 (es) 2007-10-10
NO20080942L (no) 2008-04-07
RU2008106936A (ru) 2009-11-10
GT200600432A (es) 2007-05-28
WO2007038271A1 (en) 2007-04-05
IL189650A0 (en) 2008-06-05
EP1928841A1 (en) 2008-06-11
CN101273018A (zh) 2008-09-24
KR20080050430A (ko) 2008-06-05
US20070072925A1 (en) 2007-03-29
PE20070461A1 (es) 2007-05-10
EP2256107A1 (en) 2010-12-01
ECSP088286A (es) 2008-04-28
BRPI0616757A2 (pt) 2011-06-28
US7423158B2 (en) 2008-09-09
TW200808735A (en) 2008-02-16
ZA200802636B (en) 2009-03-25
AU2006294620A1 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
CR9830A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa
CR9244A (es) AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA
CY1119669T1 (el) Παραγωγα 1-φαινυλ-2-πυριδινυλ-αλκυλ-αλκοολων ως αναστολεις φωσφοδιεστερασης
CR11020A (es) Compuestos amino-5-[-4-(difluorometoxi)fenil suatituido]-5-fenilimidazolona como inhibidores de b-secretasa
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
CR9272A (es) Amino-imidazolonas para la inhibicion de b-secretasa
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
EA201100447A1 (ru) Органические соединения
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
EA200901329A1 (ru) Применение пиридин-2-окси-3-карбонамидов в качестве защитных средств
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
EA201000269A1 (ru) Новые гербициды
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
UA106880C2 (uk) Нові гербіциди
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
EA201101099A1 (ru) Гербициды, полученные из циклопентадиона
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)